Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Acalabrutinib, oral, 100 mg BID, continuous

Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles

Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4

Obinutuzumab on days 1, 8, 15 of cycle 1, day 1 of cycles 2-6, then every 2 cycles